Compugen will present new research at AACR 2023 that allows for the accurate detection and study of novel target PVRIG.
Correcting the single cell RNA sequencing GENCODE gene model is necessary for the accurate identification and study of the novel target PVRIG, which will enhance the investigation and creation of potential new cancer immunotherapies. The new Compugen study evaluates and provides means to better interrogate the expression of PVRIG and murine TIGIT in scRNA-seq and emphasise the significance of optimising gene models and alignment algorithms to allow for accurate gene expression measurement in scRNA-seq and bulk sequencing. Additionally, the researchers’ results support detailed study of the expression of immune checkpoints in clinical and pre-clinical studies towards the development of cancer immunotherapy treatments.
Compugen, is a pioneer in computational target discovery and a clinical-stage cancer immunotherapy company. The company announced earlier this month that it will present its new research that will allow accurate detection and study of the functional relevance of the novel target PVRIG after correction of the GENCODE gene model at the American Association for Cancer Research (AACR) annual meeting. The AACR will be held in Orlando, Florida, from April 14–19, 2023.
Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen stated:
“One of the biggest challenges in bringing new treatments to cancer patients, is understanding the complex disease biology.”
“Single cell technology has revolutionized the study of cell populations, particularly immune cells and has been a key technology used by many scientists involved in cancer immunotherapy research. The research we are presenting at AACR identified an inaccuracy in the single cell gene model technology. By correcting the GENCODE gene model, the most widely used gene model in single cell analysis platforms, we believe that we are enabling a more accurate detection of PVRIG, thereby facilitating the advancement of worldwide research of this pathway. We believe that this advancement could lead to the development of new cancer immunotherapies. As a leader in the DNAM-1 axis space, targeting both PVRIG and TIGIT pathways, we are focused on proof-of-concept studies in cancer patients treated with the triple combination of our potential first-in-class anti-PVRIG, COM701 our potential best-in-class anti-TIGIT, COM902, and a PD-1 inhibitor, with the goal of maximizing clinical benefit for patients.”
To read the .pdf Abstract of the research paper, please visit:
For more information about Compugen, please visit: www.cgen.com